Paritaprevir

CAS : 1216941-48-8

Ref. 3D-AP178043

Informations sur le produit

• Nom: Paritaprevir
• Synonymes: (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, Abt 450, Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-

Description

Paritaprevir is an inhibitor drug that is used in the treatment of hepatitis C. It binds to the active site of the viral polymerase and blocks viral RNA synthesis. Paritaprevir has a half-life of about 3 hours and a concentration-time curve that results in an interactive response with wild-type virus, which may lead to antiviral resistance. Paritaprevir has been shown to be effective for patients with hepatic impairment, but it is not recommended for patients who are obese or have a body mass index greater than 30 kg/m2 because these conditions can increase the risk of adverse effects.

• Marque: Biosynth

Propriétés chimiques

• Degré de pureté: Min. 95%